Cargando…

Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey

PURPOSE: Turoctocog alfa pegol (N8-GP) is an extended half-life recombinant factor VIII molecule used for the treatment of hemophilia A (HA). The purpose of this study was to investigate real-world experiences of patients with HA treated with N8-GP. PATIENTS AND METHODS: A 25-minute online survey wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eichler, Hermann, Nagao, Azusa, Waller, John, Stuber, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661914/ https://www.ncbi.nlm.nih.gov/pubmed/38027080 http://dx.doi.org/10.2147/PPA.S394216

Ejemplares similares

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
por: Napolitano, Mariasanta, et al.
Publicado: (2021)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
por: Lentz, Steven R., et al.
Publicado: (2022)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
por: Klamroth, Robert, et al.
Publicado: (2021)

An overview of turoctocog alfa pegol (N8‐GP; ESPEROCT(®)) assay performance: Implications for postadministration monitoring
por: Ezban, Mirella, et al.
Publicado: (2019)

Reagent‐specific underestimation of turoctocog alfa pegol (N8‐GP) clotting activity owing to decelerated activation by thrombin
por: Persson, Egon, et al.
Publicado: (2018)

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
por: Napolitano, Mariasanta, et al.
Publicado: (2019)

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
por: Kearney, Susan, et al.
Publicado: (2019)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct(®))
por: Bjørnsdottir, Inga, et al.
Publicado: (2020)

Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
por: Takedani, Hideyuki, et al.
Publicado: (2015)

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
por: John, M. Joseph, et al.
Publicado: (2020)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Turoctocog alfa (NovoEight®) – from design to clinical proof of concept
por: Ezban, Mirella, et al.
Publicado: (2014)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series
por: Nagao, Azusa, et al.
Publicado: (2023)

Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro
por: Takeyama, Masahiro, et al.
Publicado: (2020)

Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
por: Wu, Runhui, et al.
Publicado: (2020)

Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
por: Matino, Davide, et al.
Publicado: (2022)

Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials
por: Tosetto, Alberto, et al.
Publicado: (2020)

Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A
por: Sanabria, Martin, et al.
Publicado: (2021)

Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule
por: Ahmadian, Haleh, et al.
Publicado: (2016)

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients
por: Chan, Anthony K., et al.
Publicado: (2020)

Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients
por: You, Chur Woo, et al.
Publicado: (2019)

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
por: Santagostino, E, et al.
Publicado: (2015)

Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa
por: Santagostino, E, et al.
Publicado: (2014)

Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials
por: Witarto, Bendix Samarta, et al.
Publicado: (2022)

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management
por: Benitez Hidalgo, Olga, et al.
Publicado: (2022)

A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States
por: Aledort, Louis, et al.
Publicado: (2020)

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
por: Patel, Nayana Hitesh, et al.
Publicado: (2023)

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study
por: Escuriola-Ettingshausen, Carmen, et al.
Publicado: (2023)

Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
Publicado: (2023)

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A
por: Korth‐Bradley, Joan, et al.
Publicado: (2018)

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A
por: George, Lindsey A, et al.
Publicado: (2015)

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial
por: Yaish, Hassan, et al.
Publicado: (2019)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1irc4mn9jbo1fucvqrc9l4lt72